Fiche publication
Date publication
juillet 2026
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BIANCO Alberto
Tous les auteurs :
Pati E, Franceschi Biagioni A, Casani R, Arellano LM, Battisti T, Garcia-Ortega G, Lozano N, Bianco A, Kostarelos K, Ballerini L, Cellot G
Lien Pubmed
Résumé
Therapeutic needs to modulate brain circuits highlight graphene-based materials (GBMs) as an emerging tool to engineer specific interventions to treat neuro-diseases. In this context, graphene oxide (GO) nanosheets offer new drug delivery strategies to reach neural cells and signaling networks selectively. To complex and transport neuropeptide Y (NPY), GO was engineered as GO:NPY, and its activity was investigated in regulating excitatory neurotransmission in NPY-positive synaptic pathways, when delivered to the amygdala, a structure mediating fear memory responses. First, it was shown that in vitro GO:NPY specifically and selectively inhibited glutamate release and suppressed synaptic enhancement via NPY receptors. In a rat model of anxiety disorder, when injected into the amygdala, GO:NPY suppressed contextual fear memory responses via activation of NPY receptors in specific synaptic pathways. This easy-to-tune GBM-based nanoplatforms promise advances in co-delivery vectors preserving the synaptic specificity needed for treating specific pathological conditions.
Mots clés
fear memory modulation, graphene oxide nanosheets, nanoplatform engineering, neuronal circuit‐specific targeting, peptide‐functionalized nanomaterials
Référence
Adv Sci (Weinh). 2026 07 31;:e76608
